Autopsy report · NCT01872182
Efficacy and Safety Study of ALS-L1023 in Patients With Abdominal Obesity of Metabolic Syndrome
Cause of deathNo reason given
Life of this trial
- Ran for about 1 year 8 months before it stopped.
- 200 participants enrolled.
- No results are posted on the registry.
Vital statistics
- Status
- Terminated
- Phase
- Phase 3
- Sponsor
- Hanmi Pharmaceutical Company Limited
- Sponsor type
- Industry
- Conditions
- Abdominal Obesity Metabolic Syndrome
- Interventions
- ALS-L1023; placebo
- Participants
- 200
- Sites
- 1
- Countries
- South Korea
Look deeper
- The official registry record (the source of truth)
- Record history: every change the sponsor made
- Open it in the database
Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.